Before anything else, the cannabis It has medicinal function known by ancient cultures, although in our times it is considered more recreational use. However, its properties manage to reach problems such as epilepsy, headache and even bone pain.
Read more: Scientists unravel the relationship between insomnia and Alzheimer's disease.
see more
Confirmed: Samsung really is producing foldable screens for…
China conducts experiments with zebrafish on the space station…
Due to the great interest of the pharmaceutical industry in exploring more of this content, 3 cannabis-based products were recently released by Anvisa, check them out:
The three products released by Anvisa are of a medicinal nature, although they are not drugs per se. In case, the Cannabidiol Belcher 150 mg/mL, to Cannabidil Aura Pharma 50 mg/mL and the canadibiol greencare 23.75 mg/ML are phytopharmaceuticals. And they all respect the limit of 0.2% of tetrahydrocannabinol established by Anvisa for the circulation of Cannabis-based products in Brazil. Understand more about types of cannabis.
In addition, the manufacture of these products is exclusive to companies with certification of Good Manufacturing Practices, and which have already passed an audit. However, Aura Pharma, Belcher and Greencare products will be manufactured in Switzerland and Colombia, respectively. In this way, the sale in Brazil receives authorization since the products meet the requirements defined by Anvisa.
With these more approvals, Brazil is moving towards the acceptance of Cannabis-based medicines. However, so far only phytopharmaceuticals can circulate, while medicines would need more detailed evaluations by doctors. For now, it is stated that scientific research has not yet been able to develop effective studies with regard to the use of medicinal cannabis.
However, more and more researchers and doctors are emerging who reaffirm the medicinal potential of cannabis and argue that approval does not involve recreational use. However, Brazil is a country of strong repression of the debate on cannabis, especially in the more conservative sectors of society and the Federal Congress. For example, there are already studies that attest to the medicinal quality of the plant for various diseases, the main one being epilepsy.